We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Performance of AclarusDx® a Blood-Based Transcriptomic Test for AD, in French Patients Newly Referred to a Memory Center (DIALOG)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02221661
Recruitment Status : Completed
First Posted : August 20, 2014
Last Update Posted : August 22, 2014
Sponsor:
Collaborator:
Information provided by (Responsible Party):

Study Description
Brief Summary:
The purpose of this study is to assess the performance of AclarusDx™, an investigational blood test detecting gene expression information, and intended to help physicians in making an Alzheimer's Disease diagnosis in patients having memory complaint and/or cognitive impairments.

Condition or disease
Cognitive Impairment Memory Complaint Clinical Investigation in Memory Centers

Detailed Description:

The objective of this study is to apply AclarusDx™ signature in 600 patients newly referred in french memory centers. Only AclarusDx™ will be added to the panel of tests usually performed at the centers to establish diagnosis. AclarusDx™ will be used for investigational use only, not for diagnostic purpose. The ultimate goal is to define the clinical utility of AclarusDx™ to provide physicians with a tool that will help them in making the diagnosis of Alzheimer's Disease (AD).

The primary objective is to estimate the prevalence of positive AclarusDx™ in patients diagnosed AD in the population of primary consultants. This population of primary consultants consists of patients with cognitive impairment and / or a memory complaint requiring specialized exploration using AclarusDx™ blood test and which may be potentially related to multiple and different etiologies.

The secondary objectives are:

  • Assess the prevalence of positive AclarusDx™ in relation to other diagnoses (MCI, vascular dementia ...) established by the physician investigator at the end of specialized assessment.
  • Identify the demographic factors anamnestic, clinical, biological and imaging associated with positivity of AclarusDx™
  • Identify the demographic factors anamnestic, clinical, biological and imaging associated with the diagnosis of AD and other diagnoses.
  • Determine the contribution of AclarusDx™ in the usual battery of tests performed for diagnostic approach to Alzheimer's disease and to identify a possible association of interest with one or more endpoints (clinical, neuropsychological, brain, biological imaging).
  • Assess: diagnostic status at 6 and 12 months, and the MMSE and IADL at 6 and 12 months.
  • assess the predictive value of AclarusDx™ achieved during the initial visit to the diagnosis of AD is 12 months.
  • Evaluate AclarusDx™ predictive value to 12 months

Study Design

Study Type : Observational [Patient Registry]
Actual Enrollment : 606 participants
Observational Model: Case-Only
Time Perspective: Cross-Sectional
Target Follow-Up Duration: 12 Months
Official Title: Non-interventional Longitudinal Study in Alzheimer Disease Diagnosis in Primary Consultants Patients With Cognitive and / or Memory Complaint Requiring Specialized Exploration Using AclarusDx® Blood Test in Memory Centers
Study Start Date : December 2011
Primary Completion Date : December 2013
Study Completion Date : December 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Memory
U.S. FDA Resources

Groups and Cohorts


Outcome Measures

Primary Outcome Measures :
  1. Estimation of the prevalence of positive AclarusDx™ among patients clinically AD diagnosed [ Time Frame: Outcome measured during one single study visit ]

    The primary outcome is to estimate the prevalence of positive AclarusDx Alzheimer patients diagnosed (excluding MCI).

    The prevalence is estimated as a percentage calculated among patients being confirmed clinically as having AD at the Memory Center and having a positive or negative AclarusDx™ result



Biospecimen Retention:   Samples With DNA
Whole blood samples collected in PAXgene® blood RNA tubes

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients with cognitive impairment and/or memory complaint justifying a first clinical investigation for diagnosis
Criteria

Inclusion Criteria:

  • male and female adult patients
  • suffering from cognitive impairment and/or memory complaint and justifying a first clinical investigation at the memory center

Exclusion Criteria:

  • patient already followed up by the memory center
  • patient unable to comply with study procedures
More Information

Responsible Party: Diaxonhit
ClinicalTrials.gov Identifier: NCT02221661     History of Changes
Other Study ID Numbers: MG/JD/11.830
First Posted: August 20, 2014    Key Record Dates
Last Update Posted: August 22, 2014
Last Verified: August 2014

Keywords provided by Diaxonhit:
Alzheimer
cognitive impairment
blood test

Additional relevant MeSH terms:
Cognitive Dysfunction
Cognition Disorders
Neurocognitive Disorders
Mental Disorders